Table 2 Comparison of clinical characteristics between survivors and non-survivors of cholinesterase inhibitor poisoning (N = 6832)
Non-survivors (N = 900) | Survivors (N = 5932) | 95% CI of difference between means or percentages | P value | |
|---|---|---|---|---|
Age, mean ± SD, years old | 62.18 ± 15.48 | 54.36 ± 16.34 | 6.682 to 8.959 | < 0.0001 |
Female Sex, N (%) | 306 (34.0) | 1732 (29.2) | 1.49 to 8.2% | 0.0033 |
Comorbidities | ||||
Diabetes mellitus, N (%) | 117(13.0) | 656 (11.1) | −0.38 to 4.4% | 0.0867 |
Hypertension, N (%) | 78 (8.7) | 831 (14.0) | 3.09 to 7.28% | < 0.0001 |
Coronary artery disease, N (%) | 17 (1.9) | 175 (3.0) | −0.097 to 2.02% | 0.0727 |
Cerebrovascular accident, N (%) | 32 (3.6) | 145 (2.4) | 0.0045 to 2.68% | 0.0506 |
Chronic renal failure, N (%) | 20 (2.2) | 33 (0.6) | 0.71 to 2.8% | < 0.0001 |
Chronic obstructive pulmonary disease, N (%) | 16 (1.8) | 95 (1.6) | −0.64 to 1.34% | 0.6967 |
Asthma, N (%) | 3 (0.3) | 42 (0.7) | −0.25 to 0.75% | 0.195 |
Liver failure, N (%) | 11 (1.2) | 19 (0.3) | 0.27 to 1.86% | < 0.0001 |
Atropine use, N (%) | 698 (77.6) | 2955 (49.8) | 0.55 to 4.69% | < 0.0001 |
Pralidoxime use, N (%) | 564 (62.7) | 2915 (49.1) | 10.1 to 17.02% | < 0.0001 |
Hemodialysis, N (%) | 59 (6.6) | 65 (1.1) | 3.94 to 7.34% | < 0.0001 |
Mechanical ventilation, N (%) | 671 (74.6) | 1339 (22.6) | 48.83 to 55.01% | < 0.0001 |
Pneumonia, N (%) | 85 (9.4) | 407 (6.9) | 0.55 to 4.69% | 0.0052 |
Hospital days, mean ± SD | 6.58 ± 12.31 | 9.61 ± 11.43 | −3.846 to −2.225 | < 0.0001 |